; (2) the average frequency with which patients receive counseling, including the rates by which such counseling is provided by such a qualifying practitioner directly, or by referral; (3) the frequency of toxicology testing, including the average frequency with which random toxicology testing is administered; (4) the average monthly patient caseload for each type of qualifying practitioner; (5) the treatment retention rates for patients; (6) overdose and mortality rates; and (7) any available information regarding the diversion of drugs by patients receiving such treatment from such a qualifying practitioner. 3004. High-quality, evidence-based opioid analgesic prescribing guidelines and report (a) Guidelines The Commissioner of Food and Drugs shall develop high-quality, evidence-based opioid analgesic prescribing guidelines for the indication-specific treatment of acute pain in the relevant therapeutic areas where such guidelines do not exist. (b) Public input In developing the guidelines under subsection (a), the Commissioner of Food and Drugs shall— (1) conduct a public workshop, open to representatives of State medical societies and medical boards, various medical specialties including pain medicine specialty societies, patient groups, pharmacists, universities, and others; and (2) provide a period for the submission of comments by the public. (c) Report Not later than the date that is 2 years after the date of enactment of this Act, the Commissioner of Food and Drugs shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate, and post on the public website of the Food and Drug Administration, a report on how the guidelines under subsection (a) will be utilized to protect the public health. (d) Updates The Commissioner of Food and Drugs shall periodically— (1) update the guidelines under subsection (a), informed by public input described in subsection (b)